Mostrar el registro sencillo del ítem

Artículo

dc.creatorMartínez Negro, Maríaes
dc.creatorSánchez Arribas, Nataliaes
dc.creatorGuerrero Martínez, Andréses
dc.creatorMoyá Morán, María Luisaes
dc.creatorTros de Llarduya, Conchitaes
dc.creatorMendicuti, Franciscoes
dc.creatorAicart, Emilioes
dc.creatorJunquera, Elenaes
dc.date.accessioned2019-12-02T10:00:41Z
dc.date.available2019-12-02T10:00:41Z
dc.date.issued2019
dc.identifier.citationMartínez Negro, M., Sánchez Arribas, N., Guerrero Martínez, A., Moyá Morán, M.L., Tros de Llarduya, C., Mendicuti, F.,...,Junquera, E. (2019). A Non-Viral Plasmid DNA Delivery System Consisting on a Lysine-Derived Cationic Lipid Mixed with a Fusogenic Lipid. Pharmaceutics, 11 (12), 1-16.
dc.identifier.issn1999-4923es
dc.identifier.urihttps://hdl.handle.net/11441/90656
dc.description.abstractThe insertion of biocompatible amino acid moieties in non-viral gene nanocarriers is an attractive approach that has been recently gaining interest. In this work, a cationic lipid, consisting of a lysine-derived moiety linked to a C12 chain (LYCl) was combined with a common fusogenic helper lipid (DOPE) and evaluated as a potential vehicle to transfect two plasmid DNAs (encoding green fluorescent protein GFP and luciferase) into COS-7 cells. A multidisciplinary approach has been followed: (i) biophysical characterization based on zeta potential, gel electrophoresis, small-angle X-ray scattering (SAXS), and cryo-transmission electronic microscopy (cryo-TEM); (ii) biological studies by fluorescence assisted cell sorting (FACS), luminometry, and cytotoxicity experiments; and (iii) a computational study of the formation of lipid bilayers and their subsequent stabilization with DNA. The results indicate that LYCl/DOPE nanocarriers are capable of compacting the pDNAs and protecting them efficiently against DNase I degradation, by forming Lα lyotropic liquid crystal phases, with an average size of ~200 nm and low polydispersity that facilitate the cellular uptake process. The computational results confirmed that the LYCl/DOPE lipid bilayers are stable and also capable of stabilizing DNA fragments via lipoplex formation, with dimensions consistent with experimental values. The optimum formulations (found at 20% of LYCl content) were able to complete the transfection process efficiently and with high cell viabilities, even improving the outcomes of the positive control Lipo2000*es
dc.description.sponsorshipEspaña, MINECO (contract numbers CTQ2015-65972-R, CTQ2015-64425-C2-1-R, CTQ2015-64425-C2-2-R, CTQ2016-80600-P and RTI2018-095844-B-I00)es
dc.description.sponsorshipEspaña, University Complutense of Madrid (project number UCMA05-33-010)es
dc.description.sponsorshipEspaña, University of Alcalá (project number CCGP2017-EXP/027)es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofPharmaceutics, 11 (12), 1-16.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcompactiones
dc.subjectgene deliveryes
dc.subjectlipoplexes
dc.subjectlysine-derived cationic lipides
dc.subjectmolecular dynamicses
dc.subjectmultilamellar aggregateses
dc.subjectplasmid DNAes
dc.subjectprotectiones
dc.subjecttransfectiones
dc.titleA Non-Viral Plasmid DNA Delivery System Consisting on a Lysine-Derived Cationic Lipid Mixed with a Fusogenic Lipides
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química Físicaes
dc.relation.projectIDcontract numbers CTQ2015-65972-R, CTQ2015-64425-C2-1-R, CTQ2015-64425-C2-2-R, CTQ2016-80600-P and RTI2018-095844-B-I00)es
dc.relation.projectIDproject number UCMA05-33-010es
dc.relation.projectIDproject number CCGP2017-EXP/027es
dc.relation.publisherversionhttp://dx.doi.org/10.3390/pharmaceutics11120632es
dc.identifier.doi10.3390/pharmaceutics11120632es
idus.format.extent16 p.es
dc.journaltitlePharmaceuticses
dc.publication.volumen11es
dc.publication.issue12es
dc.publication.initialPage1es
dc.publication.endPage16es

FicherosTamañoFormatoVerDescripción
pubpharmaceutics-11-00632.pdf3.120MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional